A Repeated-Dose Pharmacokinetic Evaluation of Dilaudid SR Tablets (Hydromorphone HCI) in Patients With Chronic Pain.

Trial Profile

A Repeated-Dose Pharmacokinetic Evaluation of Dilaudid SR Tablets (Hydromorphone HCI) in Patients With Chronic Pain.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Cancer pain
  • Focus Pharmacokinetics
  • Sponsors ALZA Corporation
  • Most Recent Events

    • 28 Jul 2009 Actual patient number (22) added as reported by ClinicalTrials.gov.
    • 28 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jul 2009 Actual end date (Aug 1999) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top